| Identification | Back Directory | [Name]
L-Valinamide, N-[[[4-[[N-(4-carboxy-1-oxobutyl)-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-... | [CAS]
1895916-23-0 | [Synonyms]
OH-Glu-Val-Cit-PAB-MMAE
L-Valinamide, N-[[[4-[[N-(4-carboxy-1-oxobutyl)-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-...
L-Valinamide, N-[[[4-[[N-(4-carboxy-1-oxobutyl)-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl- | [Molecular Formula]
C63H100N10O15 | [MOL File]
1895916-23-0.mol | [Molecular Weight]
1237.53 |
| Chemical Properties | Back Directory | [Boiling point ]
1324.5±65.0 °C(Predicted) | [density ]
1.193±0.06 g/cm3(Predicted) | [solubility ]
DMSO : 180 mg/mL (145.45 mM; Need ultrasonic) | [form ]
Solid | [pka]
4?+-.0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
OH-Glu-Val-Cit-PAB-MMAE consists a cleavable ADC linker (OH-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs)[1]. | [References]
[1] Gemma E Mudd, et al. Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer. J Med Chem. 2022 Nov 10;65(21):14337-14347. DOI:10.1021/acs.jmedchem.2c00065 |
|
|